CN101850105B - 头孢呋辛钠组合药物 - Google Patents
头孢呋辛钠组合药物 Download PDFInfo
- Publication number
- CN101850105B CN101850105B CN2010101399580A CN201010139958A CN101850105B CN 101850105 B CN101850105 B CN 101850105B CN 2010101399580 A CN2010101399580 A CN 2010101399580A CN 201010139958 A CN201010139958 A CN 201010139958A CN 101850105 B CN101850105 B CN 101850105B
- Authority
- CN
- China
- Prior art keywords
- medicinal liquid
- sodium
- medicine
- cefuroxime sodium
- cefuroxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000534 cefuroxime sodium Drugs 0.000 title claims abstract description 103
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 title claims abstract description 100
- 239000003814 drug Substances 0.000 title claims abstract description 97
- 239000002131 composite material Substances 0.000 title claims abstract description 28
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 30
- WNFHGZLVUQBPMA-JSCKKFHOSA-M Sodium glucuronate Chemical compound [Na+].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O WNFHGZLVUQBPMA-JSCKKFHOSA-M 0.000 claims abstract description 23
- 229960003180 glutathione Drugs 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 108010024636 Glutathione Proteins 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 61
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 235000003969 glutathione Nutrition 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 238000000108 ultra-filtration Methods 0.000 claims description 14
- 229940090044 injection Drugs 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 229940093181 glucose injection Drugs 0.000 claims description 7
- 238000005374 membrane filtration Methods 0.000 claims description 7
- 239000008354 sodium chloride injection Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 239000007787 solid Substances 0.000 description 18
- 238000004108 freeze drying Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000002510 pyrogen Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 6
- 229910000831 Steel Inorganic materials 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- -1 iron ion Chemical class 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000010959 steel Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960001668 cefuroxime Drugs 0.000 description 5
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 238000011082 depyrogenation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供一种头孢呋辛钠的组合药物,其特征是,头孢呋辛钠∶葡醛酸钠∶谷胱甘肽的重量份数比是0.25-2.0∶0.1-0.3∶0.02-0.04的药效成份制成;并提供所述的组合药物的制备方法;本发明头孢呋辛钠组合药物在安全性、稳定性、疗效都全面优于现有技术制备的头孢呋辛钠。
Description
技术领域
本发明涉及一种头孢呋辛钠组合药物及其制备方法。
背景技术
头孢呋辛钠为广谱第二代头孢菌素。用于治疗:呼吸系统感染,泌尿生殖系统感染,骨和关节感染,皮肤软组织感染,预防手术感染,还有败血症、脑膜炎等严重感染。是一个治病面广的药物,但其有过敏甚至过敏性休克,胃肠道恶心、呕吐、腹泻,血液、肝、肾系统损害等不良反应。消除和减轻其不良反应,其是一个大有市场前景的药物,造福人民。
发明内容
为了克服现有技术中制备的头孢呋辛钠制剂的不良反应,本发明体供一种头孢呋辛钠组合药物及其制备方法。
本发明提供的头孢呋辛钠的组合药物,由如下重量份数的药效成分制成:
头孢呋辛钠 0.25-2.0
葡醛酸钠 0.1-0.3
还原型谷胱甘肽 0.02-0.04
本发明提供制备上述药物的方法,步骤如下:
(1)取重量为所述头孢呋辛钠重量5-15倍的注射用水,搅拌下,分别把所述的头孢呋辛钠、还原性谷胱甘肽、葡醛酸钠溶解完全,得到头孢呋辛钠组合药物的溶液;
(2)用截留分子量为1500D的超滤膜超滤步骤(1)得到的药液,留取超滤得到的药液;
(3)步骤(2)得到的药液在121℃蒸汽灭菌20分钟;
(4)在灭菌后的药液冷却到20-22℃时,用8%的氢氧化钠溶液,搅拌下滴加到药液中,调整药液的pH值为7.8-8.0,再经0.22μm的膜滤过,留取滤液,将滤液用8%的盐酸调整药液的pH为6.0-7.4;
(5)测定步骤(4)得到组合药物药液中头孢呋辛钠的含量;
(6)将上述的步骤(5)制得的组合药物药液制成药剂学上头孢呋辛钠可接受的剂型:
A.按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在西林瓶中,半加塞,按常规,在冷冻干燥机的冻干箱中,冷冻干躁,使组合药物固体中残留水分≤2%,压塞、轧盖,制得头孢呋辛钠组合药物的冻干针剂;
B按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在316L不锈钢托盘中,冷冻干燥,使组合药物固体中水分≤2%,粉碎组合药物固体至60-80目,测定头孢呋辛钠含量,按常法再配制成头孢呋辛钠钠的0.9%氯化钠注射液、5%或10%葡萄糖注射液、口服制剂、喷雾剂等剂型的头孢呋辛钠组合药物。
本发明的头孢呋辛组合药物的优势有:
1.本发明采用超滤膜分离热原代替现有技术的活性炭除热原工艺。现有技术的活性炭除热原工艺,不但除热原不彻底,而且把活性炭中重金属离子及活性炭微粒污染药液,重金属离子氧化头孢呋辛钠、葡醛酸钠、还原型谷胱甘肽,尤其是3价铁离子氧化头孢呋辛、葡醛酸钠、还原型谷胱甘肽后,本身还原为2价铁离子,在光照下,2价铁离子在空气中又氧化为3价铁离子,3价铁离子再氧化头孢呋辛、葡醛酸钠、谷胱甘肽,循环往复;热原及头孢呋辛的钠氧化产物对人体产生过敏反应,本发明采用膜分离热原性物质,采用组合物药液调pH值7.8-8.0,使重金属及铁离子沉淀完全,还原剂还原性谷胱甘肽与葡醛酸钠组合型还原剂及抗毒剂,抗头孢呋辛钠在制造、储运、使用过程中在体内外的氧化、过氧化反应产生的热原及过敏反应;
2.葡醛酸钠又名葡萄糖醛酸钠,其有重要的生理作用:其一在人体内能与肝或肠内含有酚基、羟基、羧基和氨基的代谢产物、毒物或药物结合,形成无毒的葡萄糖醛酸结合物,从尿中排出体外;谷胱甘肽对化学物质中毒性肝炎、病毒性肝炎有治疗作用,对放疗、化疗患者体征及肝细胞恢复作用,对有机磷、胺基及硝基化合物重金属及有机物中毒有治疗作用,对人体过敏反应有治疗作用,有抗光氧化及过氧化作用,本发明把葡醛酸钠与谷胱甘肽组合,不仅可增强葡醛酸钠对肝损害治疗作用,而且可抗头孢呋辛钠氧化及过氧化作用,可抗头孢呋辛钠氧化及过氧化物的过敏作用;
3.本发明用截流分子量1500D的超滤膜分离热原,既比活性炭除热原工艺彻底,也比用截留分子量20000D的超滤膜分离彻底,虽然热原物质分子量大于20000D,本研究发现也有2000D的热原物质分子片断也会有热原反应,所以必需分离2000D分子量的热原片断分子。所以本发明的药物分离热原彻底,无热原反应;
4.本发明的药物由于头孢呋辛钠-葡醛酸钠-谷胱甘肽三者优势互补组合,消除药物过敏反应及氧化、过氧化反应,所以本发明药物疗效稳定、质量可控、使用安全。
具体实施方式
实施例1
本发明提供的头孢呋辛钠的组合药物,由如下重量份数的药效成分制成:
头孢呋辛钠 0.25
葡醛酸钠 0.1
还原型谷胱甘肽 0.02
本发明提供制备上述药物的方法,步骤如下:
(1)取重量为所述头孢呋辛钠重量5-15倍的注射用水,搅拌下,分别把所述的头孢呋辛钠、还原性谷胱甘肽、葡醛酸钠溶解完全,得到头孢呋辛钠组合药物的溶液;
(2)用截留分子量为1500D的超滤膜超滤步骤(1)得到的药液,留取超滤得到的药液;
(3)步骤(2)得到的药液在121℃蒸汽灭菌20分钟;
(4)在灭菌后的药液冷却到20-22℃时,用8%的氢氧化钠溶液,搅拌下滴加到药液中,调整药液的pH值为7.8-8.0,再经0.22μm的膜滤过,留取滤液,将滤液用8%的盐酸调整药液的pH为6.0-7.4;
(5)测定步骤(4)得到组合药物药液中头孢呋辛钠的含量;
(6)将上述的步骤(5)制得的组合药物药液制成药剂学上头孢呋辛钠可接受的剂型:
A.按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在西林瓶中,半加塞,按常规,在冷冻干燥机的冻干箱中,冷冻干躁,使组合药物固体中残留水分≤2%,压塞、轧盖,制得头孢呋辛钠组合药物的冻干针剂;
B按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在316L不锈钢托盘中,冷冻干燥,使组合药物固体中水分≤2%,粉碎组合药物固体至60-80目,测定头孢呋辛钠含量,按常法再配制成头孢呋辛钠钠的0.9%氯化钠注射液、5%或10%葡萄糖注射液、口服制剂、喷雾剂等剂型的头孢呋辛钠组合药物。
实施例2
本发明提供的头孢呋辛钠的组合药物,由如下重量份数的药效成分制成:
头孢呋辛钠 2.0
葡醛酸钠 0.3
还原型谷胱甘肽 0.04
本发明提供制备上述药物的方法,步骤如下:
(1)取重量为所述头孢呋辛钠重量5-15倍的注射用水,搅拌下,分别把所述的头孢呋辛钠、还原性谷胱甘肽、葡醛酸钠溶解完全,得到头孢呋辛钠组合药物的溶液;
(2)用截留分子量为1500D的超滤膜超滤步骤(1)得到的药液,留取超滤得到的药液;
(3)步骤(2)得到的药液在121℃蒸汽灭菌20分钟;
(4)在灭菌后的药液冷却到20-22℃时,用8%的氢氧化钠溶液,搅拌下滴加到药液中,调整药液的pH值为7.8-8.0,再经0.22μm的膜滤过,留取滤液,将滤液用8%的盐酸调整药液的pH为6.0-7.4;
(5)测定步骤(4)得到组合药物药液中头孢呋辛钠的含量;
(6)将上述的步骤(5)制得的组合药物药液制成药剂学上头孢呋辛钠可接受的剂型:
A.按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在西林瓶中,半加塞,按常规,在冷冻干燥机的冻干箱中,冷冻干躁,使组合药物固体中残留水分≤2%,压塞、轧盖,制得头孢呋辛钠组合药物的冻干针剂;
B按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在316L不锈钢托盘中,冷冻干燥,使组合药物固体中水分≤2%,粉碎组合药物固体至60-80目,测定头孢呋辛钠含量,按常法再配制成头孢呋辛钠钠的0.9%氯化钠注射液、5%或10%葡萄糖注射液、口服制剂、喷雾剂等剂型的头孢呋辛钠组合药物。
实施例3
本发明提供的头孢呋辛钠的组合药物,由如下重量份数的药效成分制成:
头孢呋辛钠 0.25
葡醛酸钠 0.3
还原型谷胱甘肽 0.02
本发明提供制备上述药物的方法,步骤如下:
(1)取重量为所述头孢呋辛钠重量5-15倍的注射用水,搅拌下,分别把所述的头孢呋辛钠、还原性谷胱甘肽、葡醛酸钠溶解完全,得到头孢呋辛钠组合药物的溶液;
(2)用截留分子量为1500D的超滤膜超滤步骤(1)得到的药液,留取超滤得到的药液;
(3)步骤(2)得到的药液在121℃蒸汽灭菌20分钟;
(4)在灭菌后的药液冷却到20-22℃时,用8%的氢氧化钠溶液,搅拌下滴加到药液中,调整药液的pH值为7.8-8.0,再经0.22μm的膜滤过,留取滤液,将滤液用8%的盐酸调整药液的pH为6.0-7.4;
(5)测定步骤(4)得到组合药物药液中头孢呋辛钠的含量;
(6)将上述的步骤(5)制得的组合药物药液制成药剂学上头孢呋辛钠可接受的剂型:
A.按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在西林瓶中,半加塞,按常规,在冷冻干燥机的冻干箱中,冷冻干躁,使组合药物固体中残留水分≤2%,压塞、轧盖,制得头孢呋辛钠组合药物的冻干针剂;
B按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在316L不锈钢托盘中,冷冻干燥,使组合药物固体中水分≤2%,粉碎组合药物固体至60-80目,测定头孢呋辛钠含量,按常法再配制成头孢呋辛钠钠的0.9%氯化钠注射液、5%或10%葡萄糖注射液、口服制剂、喷雾剂等剂型的头孢呋辛钠组合药物。
实施例4
本发明提供的头孢呋辛钠的组合药物,由如下重量份数的约效成分制成:
头孢呋辛钠 2.0
葡醛酸钠 0.1
还原型谷胱甘肽 0.04
本发明提供制备上述药物的方法,步骤如下:
(1)取重量为所述头孢呋辛钠重量5-15倍的注射用水,搅拌下,分别把所述的头孢呋辛钠、还原性谷胱甘肽、葡醛酸钠溶解完全,得到头孢呋辛钠组合药物的溶液;
(2)用截留分子量为1500D的超滤膜超滤步骤(1)得到的药液,留取超滤得到的药液;
(3)步骤(2)得到的药液在121℃蒸汽灭菌20分钟;
(4)在灭菌后的药液冷却到20-22℃时,用8%的氢氧化钠溶液,搅拌下滴加到药液中,调整药液的pH值为7.8-8.0,再经0.22μm的膜滤过,留取滤液,将滤液用8%的盐酸调整药液的pH为6.0-7.4;
(5)测定步骤(4)得到组合药物药液中头孢呋辛钠的含量;
(6)将上述的步骤(5)制得的组合药物药液制成药剂学上头孢呋辛钠可接受的剂型:
A.按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在西林瓶中,半加塞,按常规,在冷冻干燥机的冻干箱中,冷冻干躁,使组合药物固体中残留水分≤2%,压塞、轧盖,制得头孢呋辛钠组合药物的冻干针剂;
B按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在316L不锈钢托盘中,冷冻干燥,使组合药物固体中水分≤2%,粉碎组合药物固体至60-80目,测定头孢呋辛钠含量,按常法再配制成头孢呋辛钠钠的0.9%氯化钠注射液、5%或10%葡萄糖注射液、口服制剂、喷雾剂等剂型的头孢呋辛钠组合药物。
实施例5
本发明提供的头孢呋辛钠的组合药物,由如下重量份数的药效成分制成:
头孢呋辛钠 1.5
葡醛酸钠 0.25
还原型谷胱甘肽 0.033
本发明提供制备上述药物的方法,步骤如下:
(1)取重量为所述头孢呋辛钠重量5-15倍的注射用水,搅拌下,分别把所述的头孢呋辛钠、还原性谷胱甘肽、葡醛酸钠溶解完全,得到头孢呋辛钠组合药物的溶液;
(2)用截留分子量为1500D的超滤膜超滤步骤(1)得到的药液,留取超滤得到的药液;
(3)步骤(2)得到的药液在121℃蒸汽灭菌20分钟;
(4)在灭菌后的药液冷却到20-22℃时,用8%的氢氧化钠溶液,搅拌下滴加到药液中,调整药液的pH值为7.8-8.0,再经0.22μm的膜滤过,留取滤液,将滤液用8%的盐酸调整药液的pH为6.0-7.4;
(5)测定步骤(4)得到组合药物药液中头孢呋辛钠的含量;
(6)将上述的步骤(5)制得的组合药物药液制成药剂学上头孢呋辛钠可接受的剂型:
A.按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在西林瓶中,半加塞,按常规,在冷冻干燥机的冻干箱中,冷冻干躁,使组合药物固体中残留水分≤2%,压塞、轧盖,制得头孢呋辛钠组合药物的冻干针剂;
B按药剂学允许的头孢呋辛钠的剂量,将上述步骤(5)制备的组合药物药液无菌分装在316L不锈钢托盘中,冷冻干燥,使组合药物固体中水分≤2%,粉碎组合药物固体至60-80目,测定头孢呋辛钠含量,按常法再配制成头孢呋辛钠钠的0.9%氯化钠注射液、5%或10%葡萄糖注射液、口服制剂、喷雾剂等剂型的头孢呋辛钠组合药物。
药效学验证试验:
(1)动物选择:选择由实验动物中心制备的感染动物实验模型的小鼠,体重18-22g,雌雄各半,随机分组,每组动物50只。
(2)感染菌种:金黄色葡萄球菌致肺炎的模型小鼠、肺炎链球菌致肺炎的模型小鼠、克氏肺炎杆菌模型小鼠、流感嗜血杆菌模型小鼠四个组。
(3)感染菌量:由实验动物中心测出所试菌株的100%最小致死量(100%MLD),作为感染菌量。
(4)感染途径:菌原液用5%胃膜素稀释至所需浓度(实验动物中心确定),经尾静脉注射。
(5)试验方法:将小鼠分:A.金黄色葡萄球菌致肺炎的模型小鼠组、B.肺炎链球菌致肺炎的模型小鼠组、C.克氏肺炎杆菌组、D.流感嗜血杆菌组四个组。进行不给药对照、现有技术制备的注射用头孢呋辛钠对照、本发明药物对照。每组模型动物50只。感染后立即静注给药或口服,每隔6小时再给药一次。注意观察动物物反应,连续7天,记录小鼠死亡数。
试验结果:
项目 | A菌种感染组平均死亡率% | B菌种感染组平均死亡率% | C菌种感染组平均死亡率% | D菌种感染组平均死亡率% | 药物热反应率% | 室温存一年含量下降率% | 胃及肝不良反应率% |
不给药组 | 100 | 100 | 100 | 100 | -- | -- | -- |
500mg/kg注射用头孢呋辛钠 | 66 | 64 | 62 | 44 | 22 | 32 | 14 |
本发明药500mg/kg静注 | 24 | 32 | 26 | 16 | 0 | 6 | 0 |
本发明药500mg/kg口服 | 29 | 36 | 30 | 20 | 0 | 8 | 0 |
可见,本发明头孢呋辛钠组合药物在安全性、稳定性、疗效都全面优于现有技术制备的头孢呋辛钠。
已经根据优选实施例对本发明作了描述。应当理解的是前面的描述和实施例仅仅是为了说明本发明而已,在不偏离本发明的精神和范围的前提下,本领域的技术人员可以设计出本发明的多种替代方案,其均应被理解为在本发明的保护范围之内。
Claims (1)
1.一种抗菌组合药物,其特征是,头孢呋辛钠:葡醛酸钠:还原型谷胱甘肽的重量份数比是0.25—2.0:0.1—0.3:0.02—0.04的有效药效成分制成;
所述的组合药物制备步骤和方法如下:
(1)取重量为所述头孢呋辛钠重量5—15倍的注射用水,搅拌下,分别把所述的头孢呋辛钠、还原性谷胱甘肽、葡醛酸钠溶解完全,得到头孢呋辛钠组合药物的溶液;
(2)用截留分子量为1500D的超滤膜超滤步骤(1)得到的药液,留取超滤得到的药液;
(3)步骤(2)得到的药液在121℃蒸汽灭菌20分钟;
(4)在灭菌后的药液冷却到20—22℃时,用8%的氢氧化钠溶液,搅拌下滴加到药液中,调整药液的pH值为7.8—8.0,再经0.22μm的膜滤过,留取滤液,将滤液用8%的盐酸调整药液的pH为6.0-7.4,测定组合药物药液中头孢呋辛钠的含量;
(5)将上述的步骤(4)制得的组合药物药液制成药剂学上头孢呋辛钠可接受的剂型;
所述药剂学上可接受的剂型为头孢呋辛钠的冻干针剂、或0.9%氯化钠注射液、或5%或10%葡萄糖注射液、或口服制剂、或喷雾剂剂型的头孢呋辛钠组合药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101399580A CN101850105B (zh) | 2010-04-06 | 2010-04-06 | 头孢呋辛钠组合药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101399580A CN101850105B (zh) | 2010-04-06 | 2010-04-06 | 头孢呋辛钠组合药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101850105A CN101850105A (zh) | 2010-10-06 |
CN101850105B true CN101850105B (zh) | 2012-06-27 |
Family
ID=42801897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101399580A Active CN101850105B (zh) | 2010-04-06 | 2010-04-06 | 头孢呋辛钠组合药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101850105B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103717607A (zh) * | 2012-09-12 | 2014-04-09 | 海南卫康制药(潜山)有限公司 | 头孢呋辛钠新晶型化合物及其组合物粉针 |
CN103768069A (zh) * | 2014-01-22 | 2014-05-07 | 邓学峰 | 一种头孢他啶的组合药物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1582942A (zh) * | 2004-06-14 | 2005-02-23 | 沈阳中海生物技术开发有限公司 | 头孢呋辛钠复方制剂 |
CN1732949A (zh) * | 2005-08-16 | 2006-02-15 | 夏中宁 | 注射用头孢呋辛钠与他唑巴坦钠组合物 |
-
2010
- 2010-04-06 CN CN2010101399580A patent/CN101850105B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1582942A (zh) * | 2004-06-14 | 2005-02-23 | 沈阳中海生物技术开发有限公司 | 头孢呋辛钠复方制剂 |
CN1732949A (zh) * | 2005-08-16 | 2006-02-15 | 夏中宁 | 注射用头孢呋辛钠与他唑巴坦钠组合物 |
Non-Patent Citations (2)
Title |
---|
孙华瑜 等.,.3种头孢菌素类抗生素治疗下呼吸道感染的成本-效果分析.<海峡药学>.2009,第21卷(第11期),第219-221页. * |
陈巧玲.左氧氟沙星与头孢呋辛钠治疗呼吸道感染的疗效观察.<中外医疗>.2009,(第8期),全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN101850105A (zh) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0456418B1 (en) | Treatment of clostridium difficile diarrhoea and pseudomembranous colitis | |
Arsene et al. | Short review on the potential alternatives to antibiotics in the era of antibiotic resistance | |
RU2400218C1 (ru) | Способ повышения эффективности антибиотиков | |
CN101822679B (zh) | 盐酸头孢吡肟组合药物 | |
CN101829124B (zh) | 兽用复方磺胺嘧啶钠注射液及其制备方法 | |
CN101850105B (zh) | 头孢呋辛钠组合药物 | |
CN101991640A (zh) | 一种含十大功劳的中药组合物的制备方法及其应用 | |
CN102405935B (zh) | 鱼精蛋白复配制剂及其制备方法和应用 | |
CN101850104B (zh) | 盐酸克林霉素组合药物 | |
CN101874808A (zh) | 阿奇霉素组合药物 | |
CN101849948A (zh) | 头孢呋辛酯组合药物 | |
CN102614294B (zh) | 一种复方阿莫西林混悬注射剂及其制备方法 | |
ES2290195T3 (es) | Uso de hidratos de carbono para eliminar infecciones intestinales en animales. | |
CN101850103B (zh) | 克林霉素磷酸酯组合药物 | |
JP3890086B2 (ja) | 感染性下痢症予防及び治療用組成物 | |
Pratap et al. | Formulation and Evaluation of Phytosome Loaded Drug Delivery of Gingerol for the treatment of respiratory infection | |
EP3733176B1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof | |
CN107445977B (zh) | 一种水溶性马波沙星及其制备方法与应用 | |
CN101822686A (zh) | 硫酸头孢匹罗组合药物 | |
CN103536550A (zh) | 注射用氟氧头孢钠组合物冻干粉针 | |
CN103656611A (zh) | 一种水溶性维生素的组合药物 | |
JPS5946208A (ja) | 抗菌性組成物 | |
CN101822680B (zh) | 一种头孢匹胺组合药物 | |
CN103908674A (zh) | 一种利福霉素钠的组合药物 | |
CN101822678B (zh) | 头孢孟多酯钠组合药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231030 Address after: 334600 Industrial Plot 186, Block C, Luyang Industrial Park, Guangfeng Economic Development Zone, Guangfeng District, Shangrao City, Jiangxi Province Patentee after: Jiangxi Yuetu Medical Equipment Co.,Ltd. Address before: 334600 156 Lu Lin Avenue, Guangfeng County, Jiangxi Patentee before: Deng Xuefeng |